Abstract:Huntington's disease (HD) is a heritable neurological disorder that affects cognitive and motor performance in patients carrying the mutated huntingtin (HTT) gene. In mouse models of HD, previous reports showed a significant increase in spontaneous GABAA receptor-mediated synaptic activity in striatal spiny projection neurons (SPNs). In this study, using optogenetics and slice electrophysiology, we examined the contribution of γ-aminobutyric acid (GABA)-ergic parvalbumin (PV)- and somatostatin (SOM)-expressing interneurons to the increase in GABA neurotransmission using the Q175 (heterozygote) mouse model of HD. Patch clamp recordings in voltage-clamp mode were performed on SPNs from brain slices of presymptomatic (2 months) and symptomatic (8 and 12 months) Q175 mice and wildtype (WT) littermates. While inhibitory postsynaptic currents (IPSCs) evoked in SPNs following optical activation of PV- and SOM-expressing interneurons differed in amplitude, no genotype-dependent differences were observed at all ages from both interneuron types; however, responses evoked by either type were found to have faster kinetics in symptomatic mice. Since SOM-expressing interneurons are constitutively active in striatal brain slices, we then examined the effects of acutely silencing these neurons in symptomatic mice with enhanced Natronomonas pharaonis halorhodopsin (eNpHR). Optically silencing SOM-expressing interneurons resulted in a greater decrease in the frequency of spontaneous IPSCs (sIPSCs) in a subset of SPNs from Q175 mice compared to WTs, suggesting that SOM-expressing interneurons are the main contributors to the overall increased GABA synaptic activity in HD SPNs. Additionally, the effects of activating GABAB and cannabinoid (CB1) receptors were investigated to determine whether these receptors were involved in modulating interneuron-specific GABA synaptic transmission and if this modulation differed in HD mice. When selectively activating PV- and SOM-expressing interneurons in the presence of the CB1 receptor agonist WIN-55,212, the magnitudes of the evoked IPSCs in SPNs decreased for both interneuron types although this change was less prominent in symptomatic Q175 SPNs during SOM-expressing interneuron activation. Overall, these findings show that dysfunction of SOM-expressing interneurons contributes to the increased GABA synaptic activity found in HD mouse models and that dysregulation of the endocannabinoid system may contribute to this effect.

Restoring Compromised Cl- in D2 Neurons of a Huntingtons Disease Mouse Model Rescues Motor Disability

Enhanced Na+-K+-2Cl(-) Cotransporter 1 Underlies Motor Dysfunction in Huntington's Disease

Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease.

Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction

Developmental alterations of indirect-pathway medium spiny neurons in mouse models of Huntington's disease.

Presymptomatic Targeted Circuit Manipulation for Ameliorating Huntington's Disease Pathogenesis

Thalamocortical Projections Are Significantly Impaired in the R6/2 Mouse Model of Huntington's Disease

Potassium channel dysfunction in neurons and astrocytes in Huntington's disease

CGS21680 Attenuates Symptoms of Huntington's Disease in a Transgenic Mouse Model

Corticostriatal Maldevelopment in the R6/2 Mouse Model of Juvenile Huntington Disease

Early alterations of motor learning and corticostriatal network activity in a Huntington's disease mouse model

Impaired striatal glutathione–ascorbate metabolism induces transient dopamine increase and motor dysfunction

Corticostriatal Maldevelopment in the R6/2 Mouse Model of Juvenile Huntington's Disease

Modulating glial genes involved in synaptic function mitigates pathogenesis and behavioral deficits in a<i>Drosophila</i>model of Huntington’s Disease

Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington’s Disease Mice

Reduced Lysosomal Density in Neuronal Dendrites Mediates Deficits in Synaptic Plasticity in Huntington’s Disease

A TCF7L2-responsive suppression of both homeostatic and compensatory remyelination in Huntington disease mice

Differential impact of optogenetic stimulation of direct and indirect pathways from dorsolateral and dorsomedial striatum on motor symptoms in Huntington's disease mice

Pharmacological Co-Activation of TrkB and TrkC Receptor Signaling Ameliorates Striatal Neuropathology and Motor Deficits in Mouse Models of Huntington's Disease

Disposition of Proteins and Lipids in Synaptic Membrane Compartments is Altered in Q175/Q7 Huntington’s Disease Mouse Striatum

AAV–BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment